DOCSLIB.ORG

Selecting Topical and Systemic Agents for Recurrent Aphthous Stomatitis Drore Eisen, MD, DDS, Cincinnati, Ohio Denis P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Selecting Topical and Systemic Agents for Recurrent Aphthous Stomatitis Drore Eisen, MD, DDS, Cincinnati, Ohio Denis P continuing medical education Selecting Topical and Systemic Agents for Recurrent Aphthous Stomatitis Drore Eisen, MD, DDS, Cincinnati, Ohio Denis P. Lynch, DDS, PhD, Memphis, Tennessee GOAL To discuss topical and systemic medications used for palliation of recurrent aphthous stomatitis (RAS). OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Contrast the characteristics of recurrent aphthous stomatitis and intraoral herpes simplex virus infection. 2. Discuss topical treatments and their efficacy for RAS. 3. Summarize systemic treatments for RAS. CME Test on page 214. This article has been peer reviewed and ACCME to provide continuing medical ed- approved by Michael Fisher, MD, Professor ucation for physicians. of Medicine, Albert Einstein College of Albert Einstein College of Medicine Medicine. Review date: August 2001. designates this educational activity for a This activity has been planned and im- maximum of 1.0 hour in category 1 credit plemented in accordance with the Essen- toward the AMA Physician’s Recognition tials and Standards of the Accreditation Award. Each physician should claim only Council for Continuing Medical Education those hours of credit that he/she actually through the joint sponsorship of Albert spent in the educational activity. Einstein College of Medicine and Quadrant This activity has been planned and HealthCom, Inc. The Albert Einstein produced in accordance with ACCME College of Medicine is accredited by the Essentials. Recurrent aphthous stomatitis (RAS) is one of the scribed corticosteroids, or antimicrobial agents, most common oral diseases worldwide. Although are sufficient to control the disease. Patients with the exact etiology of RAS remains unknown, a frequent exacerbations or those with a severe variety of topical and systemic preparations may form of RAS that is unresponsive to topical treat- be used for palliation or prevention. In most ments often require systemic agents to control patients with RAS, topical agents, including over- their disease. These include corticosteroids, the-counter preparations such as amlexanox, pre- colchicine, dapsone, pentoxifylline, and thalido- mide. All therapies are palliative, and none result Dr. Eisen is in private practice in Cincinnati, Ohio. Dr. Lynch is a in permanent remission. Professor in the Department of Biologic and Diagnostic Sciences and in the Division of Dermatology, University of Tennessee ecurrent aphthous stomatitis (RAS), or Colleges of Dentistry and Medicine, Memphis. Reprints: Drore Eisen, MD, DDS, Dermatology Research canker sore, is the most common form of oral 1 Associates, 7691 Five Mile Rd, Cincinnati, OH 45230 Rulcerations in both children and adults. The (e-mail: [email protected]). clinical characteristics of RAS and differentiation VOLUME 68, SEPTEMBER 2001 201 RECURRENT APHTHOUS STOMATITIS Table 1. Clinical Characteristics of Recurrent Aphthous Stomatitis and Intraoral Herpes Simplex Virus Infection* Minor Major Herpetiform HSV RAS RAS RAS Infection Incidence Common Uncommon Rare Uncommon Location Buccal mucosa Labial mucosa All oral mucosa Hard palate Labial mucosa Soft palate Attached gingiva Lateral tongue Oropharynx Floor of mouth Number 1–10 1–5 5–100 1–10 Size, cm <1.0 >1.0 <0.3 0.1–1.0 Pain None to moderate Severe Mild to moderate None to moderate Duration, d 7–14 15–60 7–14 7–14 Scarring Rare Common None None Comments Multiple contributing History of HIV and No viral etiology History of HSV etiologic factors GI disease *RAS indicates recurrent aphthous stomatitis; HSV, herpes simplex virus; HIV, human immunodeficiency virus; GI, gastrointestinal. from ulcerations caused by intraoral herpes simplex systemic therapeutic modalities, which may pro- virus infection are outlined in Table 1. RAS is a vide symptomatic relief, are available (Table 2). multifactorial process, with the development of oral lesions influenced by trauma, smoking, stress, hor- Topical Treatments monal state, family history, food hypersensitivity, Amlexanox is a topical preparation that is effective and infectious or immunologic factors.2 Fortunately, in the treatment of RAS. The drug was approved by most cases of RAS can be managed palliatively with the US Food and Drug Administration in 1996 as the topical agents. A variety of over-the-counter prepa- first treatment for aphthous ulcers in immunocompe- rations containing one or more active ingredients, tent patients. Amlexanox is an anti-inflammatory including anesthetics, antimicrobials, wound that inhibits leukotrienes and histamines, although cleansers, coating agents, and occlusive dressings, is its exact mechanism of action in the treatment of widely available. Although many of these products RAS is unknown.3 In several double-blind, con- reduce the pain and/or shorten the duration of the trolled, multicenter studies involving more than disease, benefits are modest and attained typically in 1100 patients, amlexanox was shown to statistically patients with RAS whose ulcers are shallow, rela- accelerate complete ulcer healing and reduce the tively painless, and short in duration. time of pain resolution.4 Specifically, application of A significant number of patients with RAS amlexanox as a 5% paste to ulcerations resulted in develop painful ulcerations that result in difficulty complete resolution of pain 1.3 days sooner than no when speaking, eating, drinking, and performing treatment and 0.7 days sooner than vehicle alone. routine oral hygiene (Figure, A and B). Over- Similarly, amlexanox reduced complete healing by the-counter preparations are relatively ineffective 1.6 days compared with no treatment and by 0.7 days for these patients; however, multiple topical and compared with vehicle alone. 202 CUTIS® RECURRENT APHTHOUS STOMATITIS A B Minor aphthous ulcers (A) are small (less than 1 cm in diameter) shallow ulcers covered by a pseudomembrane and surrounded by erythema. Major aphthous ulcers (B) are larger, deeper, and heal with scar formation. Like corticosteroids, amlexanox should be multiple ulcerations. Corticosteroids are commonly applied 4 times daily (after meals and at bedtime). compounded with the occlusive dressing Orabase® Topical preparation, applied at the first sign of (Colgate-Palmolive, New York, NY), despite findings ulceration, significantly reduces pain and acceler- of a controlled study that suggests that topical ates healing. Patients may complain of burning or steroids in adhesive bases are no more effective than stinging at the site of application, but this adverse the base preparation alone.8 Patients should be reaction is transient. The vehicle, an oral paste instructed to apply topical corticosteroids 3 to 5 times specifically formulated to adhere to the oral daily and to initiate therapy during the early stage of mucosa, is well accepted by patients and often pre- lesion development. Prolonged contact of the corti- ferred to other topical agents. costeroid with the ulcerated mucosa appears to sig- Although rigorous controlled studies are lacking, nificantly increase the effectiveness of treatment. the efficacy of topical corticosteroids in the treat- Therefore, patients should massage the medication ment of RAS is indisputable based on their favorable on the ulceration for 30 to 60 seconds with their and widespread use. Furthermore, the lack of fingers or coat a cotton-tipped applicator and hold it observed or reported adverse effects of topical corti- against the ulceration for up to a minute. Eating and costeroids in the treatment of RAS and other oral drinking should be avoided for a minimum of inflammatory diseases supports their safety.5,6 30 minutes after application. Chronic topical corti- Several generalizations about topical cortico- costeroid use in the oral cavity can facilitate over- steroid use in the oral cavity may be made. Patients growth of Candida and requires careful monitoring. should be warned about the off-label use of these Although their benefits have not been substanti- agents and the accompanying package inserts, ated in multicenter trials, many antimicrobial com- which all state “for external use only.” As demon- pounds may be used to treat RAS with various strated in an open label study, superpotent topical degrees of success. For example, topically applied corticosteroids are more effective and rapid in onset antibiotics such as tetracycline and cephalexin may than weaker preparations.7,8 Because efficacy studies be helpful because of their anti-inflammatory effects.9 comparing corticosteroids in various vehicles have A solution containing a 250 or 500 mg antibiotic been performed only on the skin, choosing a vehicle capsule dissolved in 30 to 50 mL of water may be used for oral-cavity use is an inexact process that should as a rinse or to saturate gauze, which can be applied include patient preference. Ointments, unlike gels directly to the ulcer. Other antimicrobial compounds or creams, do not burn or sting when applied to including the mouthwash Listerine® (Warner- ulcerations, although they adhere poorly to mucosa. Lambert Consumer Healthcare, Morris Plains, NJ), Elixir forms of corticosteroids such as dexamethasone whose active ingredients include a mixture of essen- can be used as an oral rinse for patients with tial oils, can be used to decrease the duration and VOLUME 68, SEPTEMBER 2001 203 RECURRENT APHTHOUS STOMATITIS Table 2. Topical and Systemic Agents for Recurrent Aphthous Stomatitis* Agent Comment Topical Amlexanox Only FDA-approved drug for RAS Antibiotics
Load more

Recommended publications
  • The Use of Biologic Agents in the Treatment of Oral Lesions Due to Pemphigus and Behçet's Disease: a Systematic Review
    Davis GE, Sarandev G, Vaughan AT, Al-Eryani K, Enciso R. The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review. J Anesthesiol & Pain Therapy. 2020;1(1):14-23 Systematic Review Open Access The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review Gerald E. Davis II1,2, George Sarandev1, Alexander T. Vaughan1, Kamal Al-Eryani3, Reyes Enciso4* 1Advanced graduate, Master of Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 2Assistant Dean of Academic Affairs, Assistant Professor, Restorative Dentistry, Meharry Medical College, School of Dentistry, Nashville, Tennessee, USA 3Assistant Professor of Clinical Dentistry, Division of Periodontology, Dental Hygiene & Diagnostic Sciences, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 4Associate Professor (Instructional), Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA Article Info Abstract Article Notes Background: Current treatments for pemphigus and Behçet’s disease, such Received: : March 11, 2019 as corticosteroids, have long-term serious adverse effects. Accepted: : April 29, 2020 Objective: The objective of this systematic review was to evaluate the *Correspondence: efficacy of biologic agents (biopharmaceuticals manufactured via a biological *Dr. Reyes Enciso, Associate Professor (Instructional), Division source) on the treatment of intraoral lesions associated with pemphigus and of Dental Public Health and Pediatric Dentistry, Herman Ostrow Behçet’s disease compared to glucocorticoids or placebo. School of Dentistry of USC, Los Angeles, California, USA; Email: [email protected].
    [Show full text]
  • Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis 1Joanna Baptist, 2Shrijana Shakya, 3Ravikiran Ongole
    JCDP Rebamipide to Manage Stomatopyrosis10.5005/jp-journals-10024-1972 in Oral Submucous Fibrosis ORIGINAL RESEARCH Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis 1Joanna Baptist, 2Shrijana Shakya, 3Ravikiran Ongole ABSTRACT Source of support: Nil Introduction: Oral submucous fibrosis (OSF) causes progres- Conflict of interest: None sive debilitating symptoms, such as oral burning sensation (sto- matopyrosis) and limited mouth opening. The standard of care INTRODUCTION (SOC) protocol includes habit cessation, intralesional steroid and hyaluronidase injections, and mouth opening exercises. The Oral submucous fibrosis (OSF) is commonly seen in objective of the study was to evaluate efficacy of rebamipide the Indian subcontinent affecting individuals of all age in alleviating burning sensation of the oral mucosa in OSF in groups. It is a potentially malignant disorder caused comparison with SOC intralesional steroid injections. almost exclusively by the use of smokeless form of Materials and methods: Twenty OSF patients were divided into tobacco products. The malignant transformation rates two groups [rebamipide (100 mg TID for 21 days) and betametha- vary from 3 to 19%.1,2 sone (4 mg/mL biweekly for 4 weeks)] of 10 each by random Oral submucous fibrosis causes progressive debilitat- sampling. Burning sensation was assessed every week for 1 month. Burning sensation scores were analyzed using repeated ing symptoms affecting the oral cavity, such as burning measures analysis of variance (ANOVA) and paired t-test. sensation, loss of cheek elasticity, restricted tongue move- Results: Change in burning sensation score was significant ments, and limited mouth opening. Oral submucous (p < 0.05) in the first four visits. However, score between the fibrosis is an irreversible condition and the management 4th and 5th visit was not statistically significant (p > 0.05).
    [Show full text]
  • Management of Oral Submucous Fibrosis – an Update
    European Journal of Molecular & Clinical Medicine ISSN 2515-8260 Volume 07, Issue 5, 2020 Management Of Oral Submucous Fibrosis – An Update Aishwarya V1; Dr. A. Amudhan2, Dr. A. Amudhan Professor, Dept. of Oral Medicine and Radiology, Sree Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research, Chennai. 1. Undergraduate student, Sree Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research, Chennai. 2. Professor, Dept of Oral Medicine and Radiology, Sree Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research, Chennai. Professor, Dept. of Oral Medicine and Radiology, Sree Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research, Chennai. Email ID: [email protected] ABSTRACT: Oral submucous fibrosis (OSF) is an insidious, chronic, progressive, debilitating disease. It is mostly prevalent in the South-east Asian countries. Areca nut chewing usually causes the condition. The hallmark of the disease being sub mucosal fibrosis that affects most parts of the oral cavity, pharynx and upper third of the oesophagus and its clinical presentation depends on the stage of the disease at detection. As the disease has a spectrum of presentation, the management differs with the various stages of the disease. This article reviews the various medical management techniques of oral submucous fibrosis. KEYWORDS: Arecanut; Etiopathogenesis; Management; Oral submucous fibrosis INTRODUCTION: Oral submucous fibrosis was first described
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Caudal Stomatitis and Other Autoimmune Oral Disease
    Caudal Stomatitis and Other Autoimmune Oral Disease Yuck, no practitioner wants to deal with these cases… But treating these will benefit your patients Autoimmune Oral Disease Multiple expressions of over response of the immune system Most common are; Caudal Stomatitis Chronic Ulcerative Paradental Stomatitis Juvenile Periodontitis Caudal Stomatitis Primarily in feline patients Hallmarks in history: Oral pain Dysphagia Ptyalism Vocalizing Distinct halitosis Diagnosis of Caudal Stomatitis Primarily a diagnosis of history and oral evaluation Oral evaluation hallmarks Palatitis Glossitis Mucositis PALATOGLOSSAL FOLD PROLIFERATION, ULCERATION Other useful diagnostic tools Hypergammaglobulinemia Bartonella titer (this is of questionable clinical relevance) Histopathology almost always shows lymphoplasmacytic infiltrate with mild to moderate fibrosis Some neutrophilic infiltrate is common WHEN IN DOUBT, SUBMIT INCISIONAL BIOPSY Pathogenesis Well…This is really up for grabs. Thought to be auto-antibodies directed at the periodontal ligament There are certainly multiple etiologies and much needs to be elucidated Probable Caudal Stomatitis Unlikely Caudal Stomatitis OK, this is the big one THERAPY OF CAUDAL STOMATITIS Divide therapy into acute therapy directed at return to eating and definitive therapy directed at long term analgesia and return to function THERE IS NO CURE, WE ARE TREATING SYMPTOMS Acute Therapy 1. In anorexic, painful cats a. Analgesics 1. Opioids 2. Non-steroidal anti-inflammatories 3. Oral antibiotics
    [Show full text]
  • 2017 Oregon Dental Conference® Course Handout
    2017 Oregon Dental Conference® Course Handout Nasser Said-Al-Naief, DDS, MS Course 8125: “The Mouth as The Body’s Mirror: Oral, Maxillofacial, and Head and Neck Manifestations of Systemic Disease” Thursday, April 6 2 pm - 3:30 pm 2/28/2017 The Mouth as The Body’s Mirror Oral Maxillofacial and Head and Neck Manifestation of Ulcerative Conditions of Allergic & Immunological Systemic Disease the Oro-Maxillofacial Diseases Region Nasser Said-Al-Naief, DDS, MS Professor & Chair, Oral Pathology and Radiology Director, OMFP Laboratory Oral manifestations of Office 503-494-8904// Direct: 503-494-0041 systemic diseases Oral Manifestations of Fax: 503-494-8905 Dermatological Diseases Cell: 1-205-215-5699 Common Oral [email protected] Conditions [email protected] OHSU School of Dentistry OHSU School of Medicine 2730 SW Moody Ave, CLSB 5N008 Portland, Oregon 97201 Recurrent aphthous stomatitis (RAS) Recurrent aphthous stomatitis (RAS) • Aphthous" comes from the Greek word "aphtha”- • Recurrence of one or more painful oral ulcers, in periods of days months. = ulcer • Usually begins in childhood or adolescence, • The most common oral mucosal disease in North • May decrease in frequency and severity by age America. (30+). • Affect 5% to 66% of the North American • Ulcers are confined to the lining (non-keratinized) population. mucosa: • * 60% of those affected are members of the • Buccal/labial mucosa, lateral/ventral tongue/floor of professional class. the mouth, soft palate/oropharyngeal mucosa • Etiopathogenesis: 1 2/28/2017 Etiology of RAU Recurrent Aphthous Stomatitis (RAS): Types: Minor; small size, shallow, regular, preceeded by prodrome, heal in 7-10 days Bacteria ( S.
    [Show full text]
  • Oral Manifestations of Systemic Disease Their Clinical Practice
    ARTICLE Oral manifestations of systemic disease ©corbac40/iStock/Getty Plus Images S. R. Porter,1 V. Mercadente2 and S. Fedele3 provide a succinct review of oral mucosal and salivary gland disorders that may arise as a consequence of systemic disease. While the majority of disorders of the mouth are centred upon the focus of therapy; and/or 3) the dominant cause of a lessening of the direct action of plaque, the oral tissues can be subject to change affected person’s quality of life. The oral features that an oral healthcare or damage as a consequence of disease that predominantly affects provider may witness will often be dependent upon the nature of other body systems. Such oral manifestations of systemic disease their clinical practice. For example, specialists of paediatric dentistry can be highly variable in both frequency and presentation. As and orthodontics are likely to encounter the oral features of patients lifespan increases and medical care becomes ever more complex with congenital disease while those specialties allied to disease of and effective it is likely that the numbers of individuals with adulthood may see manifestations of infectious, immunologically- oral manifestations of systemic disease will continue to rise. mediated or malignant disease. The present article aims to provide This article provides a succinct review of oral manifestations a succinct review of the oral manifestations of systemic disease of of systemic disease. It focuses upon oral mucosal and salivary patients likely to attend oral medicine services. The review will focus gland disorders that may arise as a consequence of systemic upon disorders affecting the oral mucosa and salivary glands – as disease.
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]
  • 1532 Corticosteroids
    1532 Corticosteroids olone; Ultraderm; Malaysia: Synalar†; Mex.: Cortifung-S; Cortilona; Gr.: Lidex; Ital.: Flu-21†; Topsyn; Mex.: Topsyn; Norw.: Metosyn; Pharmacopoeias. In Br. Cremisona; Farmacorti; Flumicin; Fluomex; Fusalar; Lonason; Synalar; Philipp.: Lidemol; Lidex; Singapore: Lidex†; Spain: Klariderm†; Novoter; BP 2008 (Fluocortolone Hexanoate). A white or creamy-white, Norw.: Synalar; NZ: Synalar; Philipp.: Aplosyn; Cynozet; Synalar; Syntop- Switz.: To p s y m ; To p s y m i n ; UK: Metosyn; USA: Lidex; Vanos. ic; Pol.: Flucinar; Port.: Oto-Synalar N; Synalar; Rus.: Flucinar (Флуцинар); odourless or almost odourless, crystalline powder. It exhibits pol- Multi-ingredient: Austria: Topsym polyvalent; Ger.: Jelliproct; Topsym ymorphism. Practically insoluble in water and in ether; very Sinaflan (Синафлан); S.Afr.: Cortoderm; Fluoderm; Synalar; Singapore: polyvalent; Hung.: Vipsogal†; Israel: Comagis; Mex.: Topsyn-Y; Philipp.: Flunolone-V; Spain: Co Fluocin Fuerte; Cortiespec; Fluocid Forte; Fluoder- Lidex NGN; Spain: Novoter Gentamicina; Switz.: Mycolog N; Topsym slightly soluble in alcohol and in methyl alcohol; slightly soluble mo Fuerte; Flusolgen; Gelidina; Intradermo Corticosteroi†; Synalar; Synalar polyvalent; UK: Vipsogal. in acetone and in dioxan; sparingly soluble in chloroform. Pro- Rectal Simple; Swed.: Synalar; Switz.: Synalar; Thai.: Cervicum; Flu- ciderm†; Flunolone-V; Fulone; Supralan; Synalar; UK: Synalar; USA: Capex; tect from light. Derma-Smoothe/FS; DermOtic; Fluonid; Flurosyn†; Retisert; Synalar; Syn- emol; Venez.: Bratofil; Fluquinol Simple†; Neo-Synalar; Neoflu†. Fluocortin Butyl (BAN, USAN, rINNM) ⊗ Fluocortolone Pivalate (BANM, rINNM) ⊗ Multi-ingredient: Arg.: Adop-Tar†; Tri-Luma; Austria: Myco-Synalar; Procto-Synalar; Synalar N; Belg.: Procto-Synalar; Synalar Bi-Otic; Braz.: Butil éster de la fluocortina; Butylis Fluocortinas; Fluocortine Fluocortolone, pivalate de; Fluocortolone Trimethylacetate; Dermobel†; Dermoxin; Elotin; Fluo-Vaso; Neocinolon; Otauril†; Otocort†; Butyle; SH-K-203.
    [Show full text]
  • Fluocinoloneacetonide 0.01% and Dexamethasone 0.1% Mouthwash in the Treatment of Symptomatic Oral Lichen Planus
    Research Article Adv Dent & Oral Health Volume 3 Issue 3 - January 2017 DOI: 10.19080/ADOH.2017.03.555611 Copyright © All rights are reserved by Patnarin Kanjanabuch Fluocinolone acetonide 0.01% and Dexamethasone 0.1% Mouthwash in the Treatment of Symptomatic Oral Lichen Planus Achara Vathanasanti1 and Patnarin Kanjanabuch2* 1Department of Pharmacology, Chulalongkorn University, Thailand 2Department of Oral Medicine, Chulalongkorn University, Thailand Submission: September 30, 2016; Published: January 04, 2017 *Corresponding author: Patnarin Kanjanabuch, Department of Oral Medicine, Chulalongkorn University, Bangkok 10330, Thailand, Tel: ; Email: Abstract Purpose: The objective of this study was to compare the effectiveness of fluocinolone acetonide 0.01% and dexamethasone 0.1% mouthwashPatients in and treating Methods: symptomatic oral lichen planus (OLP). Thirty-four patients (27 females and 7 males; mean age 47.26±11.78 years) with symptomatic OLP were treated for 6 weeks with either fluocinolone acetonide 0.01% mouthwash or dexamethasone 0.1% mouthwash in a randomized, double-blind, clinical trial.Results: Pain severity and lesion size and severity were assessed using the VAS pain score and clinical score, respectively. At the end of the treatment period, pain symptoms (VAS pain score) and lesion size and severity (clinical score) were significantly lower in the fluocinolone acetonide 0.01% and dexamethasone 0.1% mouthwash groups compared with baseline. However, the difference in theseConclusion: scores between the groups was not significant. fluocinolone acetonide 0.01% and dexamethasone 0.1% mouthwash were effective in treating symptomatic OLP. However, additionalKeywords: studies using a larger population and a longer treatment period and follow-up are needed to confirm these findings.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • PRACTICAL CLINICAL COURSES V3969 Common Frustrating Oral
    PRACTICAL CLINICAL COURSES A Service of the Gordon J. Christensen Career Development Program V3969 Common Frustrating Oral Diseases – Diagnosis & Treatment John A. Svirsky, DDS, MEd Gordon J. Christensen, DDS, MSD, PhD Materials Included C.E. Instruction Sheet Products List Clinician Responsible Goals & Objectives Overview References AGD Post-Test Non-SLS Toothpastes Therapy – Treatments 1 Gordon J. Christensen PRACTICAL CLINICAL COURSES PROCEDURE FOR RECEIVING ACADEMY OF GENERAL DENTISTRY AND STATE CREDIT FOR DVDS 1. Complete the enclosed Post-Test.* For each CE Video Purchased, one test is included. If additional tests are needed, the following fees will apply: $25 per test for 1 additional dentist; $10 per test for each auxiliary (dental assistants, hygienists, lab technicians - no limit on auxiliary tests). Fees can be paid either by check or credit card when tests are submitted to Practical Clinical Courses. 2. Complete the demographic information located at the end of the test. Type of Credit: a. If the applicant selects “State,” PCC will send a certificate of verification to the applicant. The applicant must then submit this certificate to his/her state board to obtain credit. b. If the applicant selects “AGD,” PCC will submit credit information to the Academy of General Dentistry and confirmation to the applicant that it has been submitted. (The applicant may check their AGD transcript for verification – please allow 30 days.) c. If the applicant selects “Both,” PCC will complete a. & b. above. 3. Return the Post-Test portion via mail, fax, or email. Our contact information is as follows: Practical Clinical Courses 3707 N Canyon Road Suite 3D Provo, UT 84604 Fax: (801) 226-8637 [email protected] 4.
    [Show full text]